Recent Company News

• 10:01 AM ET Aug 19, 2026
  

  Transcript Intelligence: Oxford Nanopore Technologies Q2 Earnings Guidance

• 10:01 AM ET Aug 19, 2026
  

  Transcript Intelligence: Oxford Nanopore Technologies Q2 Earnings Themes

• 10:01 AM ET Aug 19, 2026
  

  Transcript Intelligence: Oxford Nanopore Technologies Q2 Earnings Q&A

• 04:21 AM ET Aug 19, 2026
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 02:04 AM ET Aug 19, 2026
  

  Oxford Nanopore Technologies reports H1 net income (£48M) vs FactSet (£65.1M) [3 est, (£68.8)-(61.6M)] (122.0000p, 0)

• 03:58 AM ET Jul 13, 2026
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (51 total)

• 02:04 AM ET Jul 13, 2026
  

  Oxford Nanopore Technologies H1 Trading Update: revenue £116.5M vs FactSet £126.1M [3 est, £123.3-129.4M]; on track to achieve adjusted EBITDA breakeven during FY27 (120.0000p, 0)

• 06:30 AM ET May 21, 2026
  

  BGI Genomics receives patent infringement litigation materials from the High Court of England and Wales (CNY 38.90, 0.00)

• 02:19 AM ET May 21, 2026
  

  Oxford Nanopore Technologies presents Technology Update at flagship annual customer conference (122.0000p, 0)

• 02:13 AM ET May 21, 2026
  

  Oxford Nanopore Technologies appoints Davide Manissero MD as Chief Medical Officer and Andrew Watson as Chief Information Officer (122.0000p, 0)